Comparative Study of Olmesartan versus Telmisartan, in Patient with Stage I Hypertension

Background: Hypertension is one of the most common diseases in the world. It is defined as sustained increase in blood pressure ≥ 140/90 mmHg. The risk of both microvascular & microvascular complications including stroke, coronary artery disease, peripheral vascular disease, retinopathy, nephropathy & possibly neuropathy increases with hypertension. Olmesartan medoxomil is a non-peptide angiotensin II receptor antagonist. The drug acts by selectively blocking angiotensin II type 1 receptor. Telmisartan is angiotensin receptor blocker shows high affinity for the angiotensin II type 1 receptors. Objective of the study is to compare the efficacy of Olmesartan and Telmisartan in Patient with stage –I hypertension. Materials and methods: This was a randomized, open‑label, parallel‑group, comparative study conducted in 120 patients of Stage I hypertension carried out from January 2021to June 2022. Patients were recruited from the cardiology outpatient department (OPD) of Shaheed Suhrawardy Medical College hospital.Results: In olmesartan group there were 39 male and 21 female patients and in telmisartan group there were 36 male and 24 female patients. Both Olmesartan and Telmisartan are effective in lowering systolic & diastolic BP at different intervals of 2nd, 4th, 8th and 12th week.  There was a statistically significant decrease in mean blood glucose level after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low‑density lipoproteins decreased significantly after 12‑week treatment with olmesartan and telmisartan. Conclusion: Olmesartan and telmisartan are equally efficacious in reducing DBP. Olmesartan, when compared to telmisartan is more efficacious in reducing SBP. Whereas Telmisartan shows the most favorable effects on FBG and lipid profile. J Shaheed Suhrawardy Med Coll 2023; 15(1): 8-12